Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 8, 2005, Pages 619-626

  Solomon, Scott R ^a   Savani, Bipin N ^a   Childs, Richard ^a   Montero, Aldemar ^a   Boss, Carol ^a   Read, Elizabeth J ^b   Leitman, Susan F ^b   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Myelodysplastic syndrome; Peripheral blood stem cell transplantation; Transplant related mortality

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RISK ASSESSMENT; SCHOOL CHILD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; VIRUS INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 22344451414     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.05.004     Document Type: Article

References (23)

1. P. Greenberg C. Cox M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079-2088
2. J.E. Anderson F.R. Appelbaum L.D. Fisher et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome Blood 82 1993 677-681
3. T.J. Nevill H.C. Fung J.D. Shepherd et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation Blood 92 1998 1910-1917
4. L. Sutton C. Chastang P. Ribaud et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients Societe Francaise de Greffe de Moelle Blood 88 1996 358-365
5. F.R. Appelbaum J. Anderson Allogeneic bone marrow transplantation for myelodysplastic syndrome outcomes analysis according to IPSS score Leukemia 12 suppl 1 1998 S25-S29
6. V. Runde T. de Witte R. Arnold et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 21 1998 255-261
7. J. Sierra W.S. Perez C. Rozman et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 2002 1997-2004
8. T. de Witte J. Hermans J. Vossen et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol 110 2000 620-630
9. P. Guardiola V. Runde A. Bacigalupo et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes Blood 99 2002 4370-4378
10. M. de Lima A. Anagnostopoulos M. Munsell et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865-872
11. J.M. Bennett D. Catovsky M.T. Daniel et al. Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 1982 189-199
12. S.R. Solomon R. Nakamura E.J. Read et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation Bone Marrow Transplant 31 2003 783-788
13. S.R. Solomon T. Tran C.S. Carter et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: A strategy for GvHD prophylaxis in allogeneic PBSC transplantation Cytotherapy 4 2002 395-406
14. K.K. Ballen D.G. Gilliland E.C. Guinan et al. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia Bone Marrow Transplant 20 1997 737-743
15. I. Yakoub-Agha P. de La Salmoniere P. Ribaud et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation J Clin Oncol 18 2000 963-971
16. H.J. Deeg B. Storer J.T. Slattery et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome Blood 100 2002 1201-1207
17. A. Bacigalupo F. Frassoni M.T. Van Lint Bone marrow or peripheral blood as a source of stem cells for allogeneic transplantation Haematologica 87 2002 4-8
18. C. Ustun O. Arslan M. Beksac et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs-host disease and relapse Biol Blood Marrow Transplant 5 1999 28-35
19. R. Childs E. Clave N. Contentin et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234-3241
20. S. Mackinnon L. Barnett G. Heller R.J. O'Reilly Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia Blood 83 1994 3409-3416
21. A. Gratwohl R. Brand J. Apperley et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia Blood 100 2002 3877-3886
22. N. Kroger M. Bornhauser G. Ehninger et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Ann Hematol 82 2003 336-342
23. R. Martino M.D. Caballero J.A. Simon et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes Blood 100 2002 2243-2245